Synonyms: BCD 132 | BCD-132 | Ivlizi®
divozilimab is an approved drug (Russia (2023))
Compound class:
Antibody
Comment: Divozilimab (BCD 132) is an anti-CD20 monoclonal antibody that was developed by Biocad.
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05730699 | Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) | Phase 3 Interventional | Biocad | ||
NCT05726630 | Clinical Study of Divozilimab in Patients With Systemic Scleroderma | Phase 3 Interventional | Biocad |